Welcome to Genvade Therapeutics

Genvade Therapeutics to Present Pipeline Progress in Cystic Fibrosis at World Orphan Drug Congress Europe 2025

Genvade Therapeutics, a biotechnology company dedicated to developing therapies for nonsense mutation-driven genetic diseases, today announced it will present the latest progress from its pipeline at the World Orphan Drug Congress Europe 2025.
The company’s lead programs target two areas of significant unmet medical need:
• Cystic Fibrosis (CF): a preclinical program designed for patients who do not benefit from existing therapies due to nonsense mutations.
• Charcot-Marie-Tooth disease (CMT): a debilitating inherited neuropathy with limited therapeutic options.

Recent non-dilutive funding from the French government (France 2030) and Bpifrance is enabling the company to accelerate development and advance rapidly toward its next milestones.